ENTPD1 and neoplasm: CD39 + tumor-reactive TILs are dysfunctional and clonally expanded; increased T cell infiltration and decreased mutational load following ICB treatment, whereas pre-existing tumor-reactive TILs have limited reinvigoration capacity and are replaced by novel clones from PBMC after treatment